Guy Young/LinkedIn
Jan 2, 2026, 03:50
Emicizumab in Infants: Not Just Cost-effective but Mandatory
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“Emicizumab in infants: not just cost-effective but mandatory.”
Author: Guy Young
Read the full article.
More posts by Flora Peyvandi on Hemostasis Today.
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion
-
Apr 3, 2026, 17:19Arun V J: Don’t Miss TRANSCON 2026 – A Direct Pathway Into India’s Clinical and Institutional Network
-
Apr 3, 2026, 17:17Louise St. Germain Bannon: Preparating for ISTH 2026 and Highlighting Best Aspects of Congress